Bridger Management LLC Invests $6.08 Million in Genmab A/S (NASDAQ:GMAB)

Bridger Management LLC bought a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 291,500 shares of the company's stock, valued at approximately $6,084,000. Genmab A/S comprises about 3.3% of Bridger Management LLC's holdings, making the stock its 11th biggest holding.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Genmab A/S by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after buying an additional 827 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares in the last quarter. Lindbrook Capital LLC lifted its position in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after acquiring an additional 1,051 shares in the last quarter. Finally, Grandfield & Dodd LLC increased its stake in shares of Genmab A/S by 4.2% in the 4th quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company's stock valued at $704,000 after purchasing an additional 1,370 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Trading Down 0.2 %

Shares of GMAB stock traded down $0.03 on Friday, hitting $19.39. 2,185,465 shares of the stock were exchanged, compared to its average volume of 1,086,414. The firm has a market capitalization of $12.43 billion, a PE ratio of 11.14, a P/E/G ratio of 2.65 and a beta of 1.04. The firm's 50 day moving average is $20.15 and its two-hundred day moving average is $20.91. Genmab A/S has a one year low of $17.24 and a one year high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.05. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on GMAB. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. HC Wainwright reissued a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. Finally, Truist Financial lowered their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.